Chimeric Antigen Receptor T-Cell
(CAR-T) Therapy

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

In 2017, the FDA approved the first ever gene immunotherapy to treat cancer. It is called chimeric antigen receptor T-cell therapy or CAR-T, for short. The one-time treatment is now being used to treat some adults and children with certain types of blood cancers.

¿Quieres leer esto en español? Haga clic aquí.

Chimeric antigen receptor T-cell therapy or CAR-T is a personalized cancer therapy that teaches the immune system’s T cells to target cancer cells

There is currently no CAR-T immunotherapy approved to treat breast cancer. But researchers are investigating whether CAR-T and other types of gene therapies might be effective in treating solid tumors, like breast cancer, and a few clinical trials have already gotten underway. The clinical trials currently studying CAR-T in breast cancer can be found here on You can learn more about how a cancer patient’s T cells are engineered in a lab to fight cancer cells in this section of the National Cancer Institute’s website.

And you can learn more about immunotherapy in general in this section of our website.

Love Research Army

We combat the disparities that exist in research by challenging the scientific community to launch studies that are as inclusive and diverse as the people that breast cancer affects.

En Español »